AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18285430 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 30
Study 18285430 — intervention group
Group type: COMPARATOR
Intervention: Control group (monitored monthly, management unchanged)
Number of subjects: 30
Study 18285430 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 15736727 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction
Number of subjects: 0
Study 15736727 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study 12796584 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant (FS)
Number of subjects: 48
Study 12796584 — intervention group
Group type: COMPARATOR
Intervention: Surgicel
Number of subjects: 48
Study 12796584 — intervention group
Group type: COMPARATOR
Intervention: Pressure
Number of subjects: 48
Study 11194702 — intervention group
Group type: COMPARATOR
Intervention: Telephone-based intervention targeting lifestyle-related health risks in seven areas (back care, cholesterol control, eating habits, exercise and activities, stress management, tobacco use, weight control) with 3-5 contacts over 1 year.
Number of subjects: 607
Study 11194702 — intervention group
Group type: COMPARATOR
Intervention: Telephone-based intervention targeting lifestyle-related health risks.
Number of subjects: 607
Study 11194702 — intervention group
Group type: COMPARATOR
Intervention: Telephone-based intervention.
Number of subjects: 607
Study 9004342 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.15 mg)
Number of subjects: 24
Study 9004342 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (15 mg)
Number of subjects: 24
Study 9004342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8300869 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtle and obvious MCMI items
Number of subjects: 241
Study 3088219 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (120 mg/m2) plus Vindesine
Number of subjects: 124
Study 3088219 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (60 mg/m2) plus Vindesine plus Mitomycin C
Number of subjects: 124
Study 3088219 — intervention group
Group type: COMPARATOR
Intervention: Vindesine alone
Number of subjects: 124
Study 3088219 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and Vindesine
Number of subjects: 124
Study 3088219 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin, Vindesine, and Mitomycin C
Number of subjects: 124
Study 3088219 — intervention group
Group type: COMPARATOR
Intervention: Vindesine
Number of subjects: 124
Study 3088219 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus Vindesine
Number of subjects: 124
Study 28786494 — intervention group
Group type: EXPERIMENTAL
Intervention: DBBM and L‐PRF mixture (test)
Number of subjects: 13
Study 28786494 — intervention group
Group type: COMPARATOR
Intervention: DBBM alone (control)
Number of subjects: 13
Study 28786494 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 13
Study 27409478 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept or ranibizumab intravitreal injections
Number of subjects: 24
Study 24988072 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of mindfulness
Number of subjects: 274
Study 24988072 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower levels of mindfulness
Number of subjects: 274
Study 24988072 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher numbers of previous episodes of depression
Number of subjects: 274
Study 22746353 — intervention group
Group type: EXPERIMENTAL
Intervention: FlexTouch (FT)
Number of subjects: 90
Study 20434886 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Awareness and Rehabilitation Training (DART)
Number of subjects: 52
Study 20434886 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Plus Information (UCI)
Number of subjects: 52
Study 18388877 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg gemfibrozil
Number of subjects: 10
Study 16186596 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem-cell transplantation (alloSCT)
Number of subjects: 472
Study 16186596 — intervention group
Group type: COMPARATOR
Intervention: No donor group (autologous SCT)
Number of subjects: 472
Study 12814477 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy
Number of subjects: 174
Study 12814477 — intervention group
Group type: COMPARATOR
Intervention: Noninduction therapy
Number of subjects: 174
Study 12814477 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell depleting antibody induction
Number of subjects: 174
Study 11420887 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release theophylline
Number of subjects: 8
Study 11420887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8855815 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol 0.1 mg/day transdermally
Number of subjects: 16
Study 8855815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1516394 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of furosemide following a single loading dose (LDCI)
Number of subjects: 9
Study 1516394 — intervention group
Group type: COMPARATOR
Intervention: Intermittent intravenous administration of furosemide (IA)
Number of subjects: 9
Study 3841410 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg atropine
Number of subjects: 32
Study 3841410 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg pirenzepine
Number of subjects: 32
Study 3841410 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg pirenzepine twice daily
Number of subjects: 32
Study 3841410 — intervention group
Group type: COMPARATOR
Intervention: 17.5 mg benzilonium bromide twice daily
Number of subjects: 32
Study 3841410 — intervention group
Group type: COMPARATOR
Intervention: 35 mg benzilonium bromide twice daily
Number of subjects: 32
Study 3841410 — intervention group
Group type: COMPARATOR
Intervention: 0.6 mg L-hyoscyamine twice daily
Number of subjects: 32
Study 31013264 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.014-inch floppy guidewire
Number of subjects: 124
Study 31013264 — intervention group
Group type: COMPARATOR
Intervention: 0.019-inch straight guidewire
Number of subjects: 124
Study 29923955 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mL/kg lipid infusion (lipid group)
Number of subjects: 12
Study 29923955 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control group)
Number of subjects: 12
Study 27861379 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 66
Study 27861379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 25517548 — intervention group
Group type: EXPERIMENTAL
Intervention: Active lidocaine hydrochloride 2% (Dynexan)
Number of subjects: 29
Study 25517548 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 29
Study 23115195 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT)
Number of subjects: 0
Study 23115195 — intervention group
Group type: COMPARATOR
Intervention: Active-Control Group
Number of subjects: 0
Study 23115195 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT) with greatest amount of practice
Number of subjects: 0
Study 19562349 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% glucose water (group B)
Number of subjects: 38
Study 19562349 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (group A)
Number of subjects: 38
Study 19087704 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 60
Study 19087704 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) treatment
Number of subjects: 60
Study 15944166 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive toy distraction
Number of subjects: 88
Study 15944166 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive movie distraction
Number of subjects: 88
Study 15944166 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 88
Study 11828229 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathology Group (PG)
Number of subjects: 18
Study 11828229 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 18
Study 9915371 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency stimulation (20 Hz)
Number of subjects: 24
Study 9915371 — intervention group
Group type: COMPARATOR
Intervention: High frequency stimulation (100 Hz)
Number of subjects: 24
Study 9915371 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation at 1/15 duty cycle
Number of subjects: 24
Study 9345448 — intervention group
Group type: EXPERIMENTAL
Intervention: BRB‐N tests administered every 60 days for 120 days
Number of subjects: 19
Study 9345448 — intervention group
Group type: EXPERIMENTAL
Intervention: PASAT results
Number of subjects: 19
Study 2264720 — intervention group
Group type: EXPERIMENTAL
Intervention: Cubital nerve block with prilocaine (15 ml of 10 mg/ml)
Number of subjects: 35
Study 2264720 — intervention group
Group type: COMPARATOR
Intervention: Haematoma block
Number of subjects: 35
Study 84901 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leucocyte interferon
Number of subjects: 4
Study 31778659 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary aerobic exercise and upper extremity repetitive task practice (VE+UERTP, n=15)
Number of subjects: 44
Study 31778659 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced aerobic exercise and upper extremity repetitive task practice (FE+UERTP, n=16)
Number of subjects: 44
Study 31778659 — intervention group
Group type: COMPARATOR
Intervention: Nonaerobic control group (control, n=13)
Number of subjects: 44
Study 30704414 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde application of bone marrow aspirate concentrate (BMAC) via coronary sinus
Number of subjects: 40
Study 30704414 — intervention group
Group type: COMPARATOR
Intervention: Standard heart failure therapy
Number of subjects: 40
Study 29960294 — intervention group
Group type: EXPERIMENTAL
Intervention: Feet reflexology (RG)
Number of subjects: 48
Study 29960294 — intervention group
Group type: COMPARATOR
Intervention: Segmental massage (SMG)
Number of subjects: 48
Study 25530510 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day immobilization with the knee in 20° of flexion postoperatively (group A, n=18)
Number of subjects: 51
Study 25530510 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week immobilization (group B, n=17)
Number of subjects: 51
Study 25530510 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week immobilization (group C, n=16)
Number of subjects: 51
Study 23623915 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 0
Study 23623915 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 0
Study 21218272 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM-tailored feedback intervention delivered via an interactive multimedia computer system
Number of subjects: 0
Study 21218272 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM-tailored feedback intervention
Number of subjects: 0
Study 19764439 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl analgesia (0.7 microg x kg(‐1) x hr(‐1) during operation, decreased to 0.5 microg x kg(‐1) x hr(‐1) next morning)
Number of subjects: 30
Study 19764439 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia (0.4 microg x kg(‐1) x hr(‐1) fentanyl and 5 ml x hr(‐1) 1% mepivacaine during operation)
Number of subjects: 30
Study 19764439 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl analgesia
Number of subjects: 30
Study 19764439 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 30
Study 17805134 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 200
Study 17805134 — intervention group
Group type: COMPARATOR
Intervention: Control (no fibrin glue)
Number of subjects: 200
Study 15061241 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE) (0.625 mg/day)
Number of subjects: 44
Study 15061241 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 44
Study 11523886 — intervention group
Group type: EXPERIMENTAL
Intervention: FOTI
Number of subjects: 29
Study 11523886 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical examination
Number of subjects: 29
Study 9551707 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg every morning for 2 weeks
Number of subjects: 12
Study 9551707 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg every morning with cimetidine 300 mg four times a day for 2 weeks
Number of subjects: 12
Study 8156961 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (PHT)
Number of subjects: 38
Study 8156961 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (VPA)
Number of subjects: 38
Study 8156961 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 38
Study 2899586 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin
Number of subjects: 0
Study 2899586 — intervention group
Group type: COMPARATOR
Intervention: Combination of netilmicin and metronidazole
Number of subjects: 0
Study 2899586 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 1105116 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 12
Study 1105116 — intervention group
Group type: COMPARATOR
Intervention: Placebo-acupuncture
Number of subjects: 12
Study 1105116 — intervention group
Group type: COMPARATOR
Intervention: Atrovent (parasympatholytic drug)
Number of subjects: 12
Study 30785361 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable comments (n = 43)
Number of subjects: 881
Study 30785361 — intervention group
Group type: COMPARATOR
Intervention: Unfavorable comments (n = 34)
Number of subjects: 881
Study 30785361 — intervention group
Group type: COMPARATOR
Intervention: No comments (n = 0)
Number of subjects: 881
Study 29110741 — intervention group
Group type: COMPARATOR
Intervention: Control flatbreads (C)
Number of subjects: 12
Study 29110741 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 % CPF with 2 % GG (GG2)
Number of subjects: 12
Study 29110741 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 % CPF with 4 % GG (GG4)
Number of subjects: 12
Study 25592008 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin-fortified formula (38 mg/100 g milk, iron 4 mg/100 g milk)
Number of subjects: 260
Study 25592008 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lactoferrin, iron 4 mg/100 g milk)
Number of subjects: 260
Study 23219989 — intervention group
Group type: EXPERIMENTAL
Intervention: Television viewing
Number of subjects: 81
Study 23219989 — intervention group
Group type: EXPERIMENTAL
Intervention: Being alone
Number of subjects: 81
Study 23219989 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving
Number of subjects: 81
Study 23219989 — intervention group
Group type: EXPERIMENTAL
Intervention: Social interaction
Number of subjects: 81
Study 21424914 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 40
Study 21424914 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 40
Study 18291276 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD)
Number of subjects: 15
Study 18291276 — intervention group
Group type: COMPARATOR
Intervention: Formocresol (FC)
Number of subjects: 15
Study 16784916 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of collaterals (Rentrop grade >1)
Number of subjects: 561
Study 16784916 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent determinants of collaterals
Number of subjects: 561
Study 12698851 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoselenium (immunorehabilitation)
Number of subjects: 55
Study 12698851 — intervention group
Group type: COMPARATOR
Intervention: Broncholytics (basic treatment)
Number of subjects: 55
Study 10952795 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-Compartment Bags (TCB)
Number of subjects: 60
Study 10952795 — intervention group
Group type: COMPARATOR
Intervention: Separate Bottles (SB)
Number of subjects: 60
Study 10952795 — intervention group
Group type: COMPARATOR
Intervention: Hospital‐Compounded Bags (HCB)
Number of subjects: 60
Study 10952795 — intervention group
Group type: EXPERIMENTAL
Intervention: All systems (SB, HCB, TCB)
Number of subjects: 60
Study 9192122 — intervention group
Group type: EXPERIMENTAL
Intervention: Step height of 6 inches
Number of subjects: 12
Study 9192122 — intervention group
Group type: EXPERIMENTAL
Intervention: Step height of 8 inches
Number of subjects: 12
Study 9192122 — intervention group
Group type: EXPERIMENTAL
Intervention: Step height of 10 inches
Number of subjects: 12
Study 9192122 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 12
Study 1372723 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing rate increased to 100 beats/min
Number of subjects: 15
Study 1372723 — intervention group
Group type: COMPARATOR
Intervention: Pacing rate remained at 70 beats/min
Number of subjects: 15
Study 1372723 — intervention group
Group type: COMPARATOR
Intervention: Pacing rate at 70 beats/min
Number of subjects: 15
Study 1372723 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing rate at 100 beats/min
Number of subjects: 15
Study 3887964 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 100
Study 3887964 — intervention group
Group type: COMPARATOR
Intervention: Chlordiazepoxide
Number of subjects: 100
Study 30763468 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Signal Therapy (PST)
Number of subjects: 25
Study 30763468 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 25
Study 29365083 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate etoposide (ET) with ART (up to 8 cycles)
Number of subjects: 190
Study 29365083 — intervention group
Group type: COMPARATOR
Intervention: As-needed etoposide (ET) with ART
Number of subjects: 190
Study 29365083 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate etoposide (ET)
Number of subjects: 190
Study 29365083 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 190
Study 27203797 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 0
Study 27203797 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 0
Study 27203797 — intervention group
Group type: EXPERIMENTAL
Intervention: N-methyl D-aspartate (NMDA) receptor antagonists
Number of subjects: 0
Study 27203797 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 0
Study 27203797 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthetics
Number of subjects: 0
Study 24721107 — intervention group
Group type: EXPERIMENTAL
Intervention: One-operator technique
Number of subjects: 352
Study 24721107 — intervention group
Group type: COMPARATOR
Intervention: Two-operator technique
Number of subjects: 352
Study 22266741 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of 0.5% bupivacaine
Number of subjects: 98
Study 22266741 — intervention group
Group type: COMPARATOR
Intervention: 3 mL of hyaluronic acid (HA)
Number of subjects: 98
Study 20720101 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention participants (dietary counseling and training on portion-size estimation)
Number of subjects: 3088
Study 20720101 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention participants
Number of subjects: 3088
Study 20720101 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention participants
Number of subjects: 3088
Study 17657474 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD65 autoantibodies (GADAs)
Number of subjects: 242
Study 16000279 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated evaluation of DAT binding ratios using a standardized 3-dimensional volume-of-interest (VOI) map
Number of subjects: 155
Study 16000279 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual evaluation of DAT binding ratios
Number of subjects: 155
Study 16000279 — intervention group
Group type: COMPARATOR
Intervention: Visual findings
Number of subjects: 155
Study 12378360 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of arterial tourniquet with pressure of 350 mmHg (group A)
Number of subjects: 80
Study 12378360 — intervention group
Group type: COMPARATOR
Intervention: No tourniquet used (group B)
Number of subjects: 80
Study 12378360 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 10332444 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone 50 mg at bedtime
Number of subjects: 51
Study 8726616 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy using 1% hydroxypolyaetoxydodecan (polidocanol)
Number of subjects: 20
Study 8726616 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (control group)
Number of subjects: 20
Study 8726616 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 20
Study 8726616 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy and Surgery (both groups)
Number of subjects: 20
Study 1914952 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback (BF)
Number of subjects: 58
Study 1914952 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (AP)
Number of subjects: 58
Study 1914952 — intervention group
Group type: COMPARATOR
Intervention: Cinnarizine (Cin)
Number of subjects: 58
Study 7008212 — intervention group
Group type: EXPERIMENTAL
Intervention: Crithidia luciliae test
Number of subjects: 93
Study 7008212 — intervention group
Group type: COMPARATOR
Intervention: Radioimmunoassay technique
Number of subjects: 93
Study 31785536 — intervention group
Group type: EXPERIMENTAL
Intervention: Any alcohol use
Number of subjects: 220
Study 31785536 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhealthy alcohol use (UAU)
Number of subjects: 220
Study 31785536 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy episodic drinking (HED)
Number of subjects: 220
Study 30993684 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (n = 29) received two 75-min lessons on evaluating the credibility of online content.
Number of subjects: 67
Study 30993684 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 38) did not receive the intervention.
Number of subjects: 67